CXCL8 and neoplasm: HMGB1 was discovered to bind the Receptor of Advanced Glycation Endproducts (RAGE) receptor on glioma cells in vitro, resulting in the activation of NF-κB and subsequent upregulation of IL-8 expression, thereby promoting tumor progression in breast cancer.